Roche: ovarian cancer drug fails trial
(CercleFinance.com) - Roche announced on Monday a failure in its IMagyn050 Phase III trial, evaluating a first-line treatment for women with newly diagnosed advanced ovarian cancer.
According to the pharmaceutical company, this study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not achieve its primary endpoint of progression-free survival.
The Swiss group also reported that based on the study data, the safety of Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.
Copyright (c) 2020 CercleFinance.com. All rights reserved.